

1 **Pre-Pandemic COVID-19 in New York City: A descriptive analysis of**
2 **COVID-19 illness prior to February 29, 2020**

3 **Page Keating, MSPH¹, Jessica Sell, MPH¹, Judy Chen¹, Joel Ackelsberg MD, MPH¹,**
4 **Winfred Wu, MD¹, Benjamin Tsoi, MD, MPH¹, Don Weiss, MD, MPH¹**

5 ¹New York City Department of Health and Mental Hygiene, Long Island City, Queens, New
6 York, USA

7 *Corresponding author: Page Keating, pkeating1@health.nyc.gov*

8 Word count- 1828

9 **Key Points** (<40 words)

10 Records of 86 persons with confirmed COVID-19 and symptom onset prior to February 29, 2020
11 were reviewed for likelihood of early onset COVID-19. Thirty-nine likely early onset COVID-19
12 cases were identified, suggesting that early COVID-19 transmission in NYC went undetected.

13

14

15

16

17

18

19 **Abstract** (<250 words)

20 **Background:** On January 30, 2020 the COVID-19 pandemic was declared a Public Health
21 Emergency of International Concern (PHEIC) by the World Health Organization. Almost a
22 month later on February 29, 2020, the first case in New York City (NYC) was diagnosed.

23 **Methods:** Three-hundred-sixty persons with COVID-like illness was reported to the NYC
24 Department of Health and Mental Hygiene (DOHMH) before February 29, but 37 of these tested
25 negative and 237 were never tested for SARS-COV-2. Records of 86 persons with confirmed
26 COVID-19 and symptom onset prior to February 29, 2020 were reviewed by four physician-
27 epidemiologists. Case-patients were classified as likely early onset COVID-19, or insufficient
28 evidence to determine onset. Clinical and epidemiological factors collected by DOHMH and
29 supplemented with emergency department records were analyzed.

30 **Results:** Thirty-nine likely early onset COVID-19 cases were identified. The majority had severe
31 disease with 69% presenting to an ED visit within 2 weeks of symptom onset. The first likely
32 COVID-19 case on record had symptom onset on January 28, 2020. Only 7 of the 39 cases
33 (18%) had traveled internationally within 14 days of onset (none to China).

34 **Conclusions:** SARS-CoV-2 and COVID-19 was in NYC before being classified as a PHEIC,
35 and eluded surveillance for another month. The delay in recognition limited mitigation effort and
36 by the time that city and state-wide mandates were enacted 16 and 22 days later there was
37 already community transmission.

38 **Keywords:** COVID-19; COVID-19 Testing; New York City; surveillance; pandemic

39

40 **Background**

41 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-
42 19, was declared a Public Health Emergency of International Concern by the World Health
43 Organization (WHO) on January 30, 2020 (1). The first case of COVID-19 was diagnosed in
44 New York City (NYC) on February 29, 2020 (2, 3). In January and most of February 2020,
45 COVID-19 diagnostic testing was only available at the U.S. Centers for Disease Control and
46 Prevention (CDC) and was restricted to patients with severe illness, known exposure, or travel
47 history from affected areas (4). The exponential spread of COVID-19 in March 2020 prompted
48 the NYC Department of Health and Mental Hygiene (DOHMH) to suspect that multiple
49 introductions and sustained transmission had occurred in January and February of 2020 (2). In
50 this report, we review medical and investigation records of case-patients with confirmed
51 COVID-19 who reported symptom onset prior to February 29, 2020. The objective of this
52 analysis was to identify COVID-19 cases that might have been diagnosed before February 29,
53 2020, had sufficient diagnostic resources been available, to inform surveillance testing criteria in
54 advance of the next pandemic.

55 **Methods**

56 NYC residents reported to the DOHMH with confirmed COVID-19 and symptom onset
57 between January 1 and February 29, 2020 were eligible for the study. Symptom onset date was
58 obtained through case investigations when providers contacted DOHMH seeking laboratory
59 testing for suspect cases of COVID-19. COVID-19 was considered confirmed when case-
60 patients either had a positive molecular SARS-CoV-2 laboratory report received electronically
61 through the New York State Electronic Clinical Laboratory Reporting System (5), or for

62 deceased individuals had COVID-19 listed as a cause of death on the death certificate. Probable
63 cases include those who tested positive for SARS-CoV-2 by antibody (one case-patient with
64 MIS-C), or those who were symptomatic contacts of confirmed cases without laboratory
65 confirmation of disease. Patient demographics, symptom information, comorbidities,
66 epidemiological risk factors for COVID-19 exposure (i.e., travel history, known exposure, high-
67 risk occupation^{*}), and illness severity indicators and outcomes (i.e., hospitalization, intensive
68 care, death) were collected by DOHMH staff. Supplemental clinical information was collected
69 from emergency department (ED) records.

70 Confirmed cases of COVID-19 with reported symptom onset between January 1 and February
71 29, 2020 were reviewed by four COVID-19 response physician-epidemiologists. Case-patients
72 were categorized as either likely to have had COVID-19 onset prior to February 29, 2020, or
73 with insufficient evidence to determine early case infection status (prior to February 29, 2020).
74 We considered initial symptoms; date of symptom onset; clinical findings on presentation to
75 medical providers, if available; date of first positive molecular[†] SARS-CoV-2 test, and time
76 lapse between symptom onset and diagnostic test. If symptoms occurred 21 days or less before
77 the positive diagnostic test, this was considered suggestive of the onset date of COVID-19. If the
78 physician-epidemiologists agreed independently with the infection status designation, case-
79 patients were classified accordingly. All physician-epidemiologist discrepancies were
80 adjudicated through deliberation amongst all four physician-epidemiologists. When consensus
81 was not reached, case-patients were assigned to the “insufficient evidence” category.

^{*} High-risk occupations include those with frequent face-to-face contact with people, such as teachers, health care workers, construction workers, security workers, entertainment industry employees, clergy, conveyance drivers, and personal care services.

[†] One patient diagnosed with MIS-C was diagnosed by antigen

82 We describe case-patient demographics, epidemiological risk factors, and symptom-based
83 classification meeting the COVID-19 Council for State and Territorial Epidemiologists (CSTE)
84 case definition for COVID-19-like-illness (CLI)(6). Analyses were conducted using SAS
85 software (version 9.4; SAS Institute) and R (version 3.6.3; The R Foundation).

86 **Results**

87 We identified 360 individuals who were reported to the DOHMH before February 29, 2020 with
88 CLI. Thirty-seven case-patients tested negative for SARS-CoV-2 and 237 were never tested. The
89 remaining 86 were designated for physician-epidemiologist review; 39 (45%) were categorized
90 as likely having had COVID-19 with onset prior to Feb 29, 2020, with the remainder (n=47)
91 having insufficient evidence to confirm early case infection status (Figure 1). The case-patients
92 with likely early onset COVID-19 (n=39) had a median age of 52 years (IQR 39-64). Most
93 (56%) were male and resided in Brooklyn (33%), Manhattan (23%), Queens (21%), Bronx
94 (18%), and Staten Island (5%). Thirty-three percent were White, 15% Black, and 33.3%
95 Hispanic. Twenty-three percent worked in high-risk occupations and 18% reported international
96 travel in the two weeks prior to onset, though none from China (Table 1).

97 Illness onset for the earliest likely COVID-19 case-patient was January 28, 2020, and most
98 (69/86, 80%) who met review criteria had onset in the last 2 weeks of February (Figure 2).
99 Common symptoms reported by case-patients were fever (92%), cough (89%), shortness of
100 breath (57%), myalgia (46%) and chills (41%). Twenty-seven (69%) of the patients had either
101 pneumonia (19 case-patients) or acute respiratory disease syndrome (ARDS, 8 case-patients)
102 (Table 1). Nearly all likely early onset case-patients met the CSTE definition for CLI (95%,
103 Table 1). Approximately half (49%) presented with CLI to an NYC ED within two weeks of

104 symptom onset. The average number of days between symptom onset and diagnosis date was 16
105 days (IQR: 10-28) for likely early onset COVID-19 case-patients and 54 days (IQR: 35-86) for
106 those with insufficient evidence to characterize COVID-19 status. The average number of days
107 between diagnosis and ED visit was 17.5 days (IQR: 0-29) and 35 days (IQR: 0-66), respectively
108 for likely COVID-19 cases and for those with insufficient evidence to characterize.
109 Additionally, case-patients for whom there was insufficient evidence to verify their onset date
110 more often were women, Black or Hispanic, resided in the Bronx or Queens, and had not
111 traveled or worked in a high-risk occupation.

112 **Discussion**

113 This analysis expands upon a previous DOHMH report and provides insight into the timing of
114 NYC's first COVID-19 wave, which caused over 200,000 cases and 18,000 deaths (2). The
115 demographic characteristics of the likely early onset COVID-19 cases mirror those of the NYC
116 population as does the distribution of cases across the five boroughs. A total of 360 individuals
117 were reported to DOHMH with COVID-19-like symptoms, and the earliest case-patient with
118 likely SARS-CoV-2 infection had onset on January 28, 2020. This person had not traveled and
119 worked in a high-risk occupation. While our retrospective analysis identified 39 likely cases of
120 COVID-19 prior to February 29, there undoubtedly were many more undetected COVID-19
121 cases in NYC. Only the most severely ill suspected COVID-19 cases, as reflected by the 69%
122 with either pneumonia or ARDS, were tested with the newly available diagnostic test. Of the 360
123 individuals reported to DOHMH during the time period, 237 were not tested.

124 These findings illustrate that community transmission was occurring at least a month prior to
125 recognition of the first case and indicate that the surveillance strategy was inadequate.

126 Supporting evidence for this conclusion comes from a NYC hospital network that tested stored

127 respiratory specimens for SARS-CoV-2 and demonstrated that the virus was likely circulating in
128 late January 2020 or possibly earlier (7, 8).

129 The shortage of SARS-CoV-2 diagnostic laboratory supplies early in the pandemic hindered
130 surveillance efforts. CDC's criteria limited testing to persons who had evidence of lower
131 respiratory illness and travel to Wuhan City, China (9). Since a small proportion of COVID-19
132 cases would have resulted in hospitalization, most would not have met criteria and been
133 undetected (10). We, and other cities, endeavored in February 2020 to collect, and CDC agreed
134 to test, pooled influenza negative specimens from emergency department visits in order to
135 determine whether SARS-CoV-2 was circulating in NYC; however, we were unable to begin
136 specimen collection until early March 2020 (11, 12).

137 Investments to improve federal capacity to quickly manufacture and distribute diagnostic test kits
138 are a priority, but we contend that the approach to pre-pandemic surveillance also needs to be
139 reconsidered. When a pandemic virus emerges, public health creates a surveillance case
140 definition to identify suspect cases for investigation. Case definitions are often crafted to identify
141 patients with severe disease because they are most likely to come to medical attention.

142 Conventional public health wisdom has been to assume that initial cases will have traveled from
143 the geographic area of origin. However, if mild, non-specific disease predominates, and the virus
144 spreads quickly, as occurred with SARS-CoV-2, a surveillance strategy of severe illness in
145 travelers will likely miss the early introduction. Surveillance criteria should be broadened based
146 on available epidemiology data to detect the entire spectrum of disease of a novel virus's entry
147 into a population. Although the preliminary epidemiology data from China was sparse, a
148 respiratory pathogen with person-to-person transmission would be expected to affect individuals
149 with frequent face-to-face contact with others, especially contact with persons reporting recent

150 travel. With the ease and speed of international travel areas of the world other than the initial
151 outbreak zone should be included in surveillance criteria. The importation of SARS-CoV-2 into
152 NYC has been linked to strains circulating in European countries (7).

153 If, or perhaps when, another novel virus emerges there again may be periods of limited testing
154 capacity. When distributing a limited resource, such as diagnostic testing, consideration must
155 also be given to vulnerable populations and those who historically have had inadequate access to
156 care (13). Additionally, provisions should be made for pre-designated sentinel sites to collect
157 specimens for pooled testing or appropriately stored for later analysis. Wastewater surveillance
158 holds promise of early pandemic awareness if it can reliably detect and identify sequences of
159 both known and novel pathogens (14).

160 Our review was limited by recall bias. Case-patients reviewed were often tested, interviewed, or
161 went to the ED weeks after their symptom onset. Therefore, we adopted a conservative approach
162 to classification, requiring verification of onset dates by medical or hospitalization records, to
163 strengthen the plausibility of a single, continuous illness between symptom onset and diagnosis.
164 All those classified as early COVID-19 cases were diagnosed with a molecular SARS-CoV-2
165 test. Although the blueprint for diagnostic tests for SARS-CoV-2 was published by WHO within
166 a month of the sequence publication (15), it took another month for the CDC to release its
167 diagnostic test (10). Even by the end of February testing availability was limited, hence our study
168 could not capture individuals who were symptomatic and either never tested or tested negative
169 after viral clearance.

170 NYC closed schools on March 16, 2020 and implemented “Pause,” the closure of all non-
171 essential business in New York State, on March 22, 2020. Whether the knowledge that SARS-
172 CoV-2 was circulating in NYC in late January would have prompted an earlier response is

173 speculative, however, by the time authorities implemented population-based control measures
174 community transmission of COVID-19 was already widespread. And while we cannot be certain
175 when the first COVID-19 case occurred in NYC, or how many introductions propelled the first
176 NYC wave, the delay in recognition limited the effectiveness of mitigation efforts. Our study
177 adds to the body of evidence that pandemics can grow quickly and undetected, and that our
178 ability to identify early introductions is paramount to the control efforts (7, 8). There is little
179 doubt that community transmission of SARS-CoV-2 accelerated quietly and rapidly in NYC
180 without detection before the pandemic's arrival was announced officially on February 29, 2020.

181

182 **Funding**

183 This work was supported by the Centers for Disease Control and Prevention (CDC)
184 Epidemiology and Laboratory Capacity Grant [grant number 6 NU50CK000517-02].

185 **Conflicts of Interest**

186 None of the authors of this manuscript had conflict of interests.

187 **Acknowledgments**

188 Marcelle Layton, Incident Command System Surveillance and Epidemiology Section, New York
189 City Department of Health and Mental Hygiene

190 References

- 191 1. (WHO) WHO. Statement on the second meeting of the International Health Regulations (2005)
192 Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV).
193 [https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-
194 health-regulations-\(2005\)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-
195 ncov\)](https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-
194 health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-
195 ncov)); WHO; 2020.
- 196 2. Thompson CN, Baumgartner J, Pichardo C, Toro B, Li L, Arciuolo R, et al. COVID-19 Outbreak -
197 New York City, February 29-June 1, 2020. *MMWR Morb Mortal Wkly Rep.* 2020; 69:1725-9.
- 198 3. Cuomo A. Governor Cuomo Issues Statement Regarding Novel Coronavirus in New York. This
199 evening we learned of the first positive case of novel coronavirus.
200 [https://www.governor.ny.gov/news/governor-cuomo-issues-statement-regarding-novel-coronavirus-
201 new-york](https://www.governor.ny.gov/news/governor-cuomo-issues-statement-regarding-novel-coronavirus-
201 new-york); New York State; 2020.
- 202 4. Prevention CfDca. Update and Interim Guidance on Outbreak of 2019 Novel Coronavirus (2019-
203 nCoV). In: Response CfPa, editor.: CDC Health Alert Network (HAN); 2020.
- 204 5. Health NYSDo. Electronic Clinical Laboratory Reporting System. Website for the State of New
205 York: Department of Health; 2011 [cited 2021 September 20]; Available from:
206 https://www.health.ny.gov/professionals/reportable_diseases/eclrs/.
- 207 6. Epidemiologists CoSaT. Update to the standardized surveillance case definition and national
208 notification for 2019 novel coronavirus disease (COVID-19). Committee: Infectious Disease. CSTE
209 Position Statement Archive Online: <https://www.cste.org/page/PositionStatements>; 2021. p. 22.
- 210 7. Hernandez MM, Gonzalez-Reiche AS, Alshammary H, Fabre S, Khan Z, van De Guchte A, et al.
211 Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave. *Nature*
212 *Communications.* 2021; 12:3463.
- 213 8. Althoff KN, Schlueter DJ, Anton-Culver H, Cherry J, Denny JC, Thomsen I, et al. Antibodies to
214 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program
215 Participants, 2 January to 18 March 2020. *Clinical Infectious Diseases.* 2021.
- 216 9. Patel A, Jernigan DB, nCoV VDCRRT. Initial Public Health Response and Interim Clinical Guidance
217 for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020. *MMWR*
218 *Morb Mortal Wkly Rep.* 2020; 69:140-6.
- 219 10. Reese H, Iuliano AD, Patel NN, Garg S, Kim L, Silk BJ, et al. Estimated Incidence of Coronavirus
220 Disease 2019 (COVID-19) Illness and Hospitalization-United States, February-September 2020. *Clin Infect*
221 *Dis.* 2021; 72:e1010-e7.
- 222 11. Bushman D, Alroy KA, Greene SK, Keating P, Wahnich A, Weiss D, et al. Detection and Genetic
223 Characterization of Community-Based SARS-CoV-2 Infections - New York City, March 2020. *MMWR*
224 *Morb Mortal Wkly Rep.* 2020; 69:918-22.
- 225 12. Spellberg B, Haddix M, Lee R, Butler-Wu S, Holtom P, Yee H, et al. Community Prevalence of
226 SARS-CoV-2 Among Patients With Influenzalike Illnesses Presenting to a Los Angeles Medical Center in
227 March 2020. *JAMA.* 2020.
- 228 13. Lieberman-Cribbin W, Alpert N, Flores R, Taioli E. Analyzing disparities in COVID-19 testing
229 trends according to risk for COVID-19 severity across New York City. *BMC Public Health.* 2021; 21:1717.
- 230 14. Kirby AE, Walters MS, Jennings WC, Fugitt R, LaCross N, Mattioli M, et al. Using Wastewater
231 Surveillance Data to Support the COVID-19 Response - United States, 2020-2021. *MMWR Morb Mortal*
232 *Wkly Rep.* 2021; 70:1242-4.
- 233 15. DZIF. Researchers develop first diagnostic test for novel coronavirus in China- January 16 2020.
234 In: Drosten C, editor. [https://www.dzif.de/en/researchers-develop-first-diagnostic-test-novel-
235 coronavirus-china](https://www.dzif.de/en/researchers-develop-first-diagnostic-test-novel-
235 coronavirus-china); DZIF; 2020.

236

237 **Table:** Demographics and clinical information for likely cases of COVID-19 and case-patients
 238 with insufficient evidence to determine COVID-19 status.

	Likely Case of Early Onset COVID-19	Insufficient Evidence to Determine
N (%)	39 (45%)	47 (55%)
Died	13 (15%)	19 (22%)
Age (median, IQR[±])	52 (39 – 64)	58 (45 – 63.5)
Gender		
Male	22 (56%)	20 (43%)
Female	16 (41%)	27 (57%)
Transgender	1 (3%)	0 (0%)
Race / Ethnicity		
Asian	5 (13%)	2 (4%)
Black / African American	6 (15%)	11 (23%)
Hispanic / Latino	13 (33%)	24 (51%)
White	13 (33%)	8 (17%)
Other	0 (0%)	1 (1%)
Unknown	2 (5%)	1 (1%)
Borough		
Bronx	7 (18%)	12 (26%)
Brooklyn	13 (33%)	16 (34%)
Manhattan	9 (23%)	4 (8%)
Queens	8 (21%)	14 (30%)
Staten Island	2 (5%)	1 (2%)
Met the CSTE[‡] definition of CLI[§]	37 (95%)	39 (83%)
Fever	34 (92%)	29 (69%)
Cough	33 (89%)	26 (62%)
Shortness of breath	21 (57%)	24 (57%)
Myalgia	17 (46%)	16 (38%)
Chills	15 (41%)	16 (38%)
Loss of taste or smell	1 (3%)	7 (17%)
Congestion or runny nose	8 (22%)	5 (12%)
Diarrhea	15 (41%)	8 (19%)
Nausea or vomiting	2 (5%)	5 (12%)

Clinical Indications		
Acute Respiratory Distress Syndrome	8 (21%)	4 (9%)
Pneumonia	19 (49%)	11 (23%)
ED[□] Visit within 2 weeks of symptom onset	27 (69%)	15 (32%)
Presented with CLI	19 (49%)	5 (11%)
Other Risk Factors		
Travel outside of country ≤14 days of onset	7 (18%)	1 (2%)
High-risk occupation	9 (23%)	4 (9%)
Days between Onset and Diagnosis Date		
Median days (IQR)	16 (10-28)	54 (35-86)

239

240 [±] Interquartile range

241 [≠] Council of State and Territorial Epidemiologists

242 [§] COVID-19-like illness

243 [□] Emergency department

244

245

246

247


248

249

250

251

252 **Figure 1:** Case classification for Medical Epidemiological Review



253

254

255

256

257

258


259

260

261

262

263 **Figure 2:** Suspected early onset cases of COVID-19 by symptom onset date and early onset case
264 classification (likely early onset vs insufficient evidence).



265